Menu

A Molecule to Treat Obesity?

GDF-15 lowers body weight in mice and primates.

Oct 18, 2017
Ashley P. Taylor

Crystal structure of a new engineered protein for treating obesity in laboratory animals. Y. XIONG ET AL., SCIENCE TRANSLATIONAL MEDICINE (2017)Researchers at the biopharmaceutical company Amgen have identified a protein that seems to help obese mice and primates to lose weight, as they report in a study published today (October 18) in Science Translational Medicine.

“This group really seemed to go a long way toward identifying what may be an interesting new approach to treatment, and that’s fantastic,” Paul Kenny, chair of the neuroscience department at Mount Sinai Health System in New York, tells Scientific American, adding that “key will be [determining] if it’s safe in humans.”

The researchers identified this protein, macrophage inhibitory cytokine 1/growth differentiation factor 15 (GDF15), through a microarray screen for secreted proteins that were differentially expressed between obese and lean mice. GDF15 is upregulated in the fat tissue and livers of obese animals, they found. Additionally, obese mice, rats, and humans have higher blood levels of GDF15 than do their lean counterparts.

After the researchers used a virus to administer the protein to obese mice, the animals’ weights dropped. Their levels of cholesterol, blood insulin, and food intake all decreased as well. Further, administering recombinant human GDF15 (produced in cultured cells) to obese mice and monkeys led the animals to lose weight and eat less.

Next, the team added an antibody fragment to the protein to make it last longer in the body, and its weight loss-inducing effects remained: monkeys injected with the protein lost 10 percent of their body weight over six weeks, New Scientist reports.

The researchers found that the protein delays the rate at which the stomach empties itself. They also found that it seems to change animals’ tastes so that they will choose normal chow over a high-fat alternative. (Animals not given GDF15 will take the high-fat option.) These changes in gastric emptying rates and food preferences also occur after bariatric surgery, the authors note.

A potential mechanism is that GDF15 binds to nerves in the gut, which in turn signal to the area postrema, a brain region that regulates appetite, New Scientist reports.

Amgen is not the only company trying to develop GDF15 drugs, New Scientist notes: Janssen, NGM Bio, Eli Lilly, and Novo Nordisk are also in the mix.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.